Limits...
Relationship of coregulator and oestrogen receptor isoform expression to de novo tamoxifen resistance in human breast cancer.

Murphy LC, Leygue E, Niu Y, Snell L, Ho SM, Watson PH - Br. J. Cancer (2002)

Bottom Line: All cases were oestrogen receptor +, node negative, primary breast tumours from patients who later had no disease progression (tamoxifen sensitive) or whose disease progressed while on tamoxifen (tamoxifen resistant).Using an antibody to oestrogen receptor-beta that detects multiple forms of this protein (total) but not an antibody that detects only full-length oestrogen receptor-beta 1, it was found that high total oestrogen receptor beta protein expressors were more frequently observed in tamoxifen sensitive tumours than resistant tumours (Fisher's exact test, P=0.046).Altogether, there is little evidence for altered coregulators expression in breast tumours that are de novo tamoxifen resistant.

View Article: PubMed Central - PubMed

Affiliation: Manitoba Institute of Cell Biology, University of Manitoba, Faculty of Medicine, Winnipeg, Manitoba, Canada, R3E OW3. lcmurph@cc.umanitoba.ca

Show MeSH

Related in: MedlinePlus

Examples of immunohistochemistry using the IgYERβ503 antibody which recognises most ORβ isoforms: (A) normal human breast tissue; (B) ORβ negative human breast tumour, H-score=25; (C) ORβ low expressing human breast tumour, H-score=100; (D) ORβ high expressing human breast tumour, H-score=225.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2376286&req=5

fig2: Examples of immunohistochemistry using the IgYERβ503 antibody which recognises most ORβ isoforms: (A) normal human breast tissue; (B) ORβ negative human breast tumour, H-score=25; (C) ORβ low expressing human breast tumour, H-score=100; (D) ORβ high expressing human breast tumour, H-score=225.

Mentions: IgYERbeta503 is an antibody that recognises ligand binding and non-ligand binding ORβ protein isoforms (Horvath et al, 2001; Saji et al, 2000) and which we refer to as total ORβ protein. Normal breast tissue was used as a positive control and is shown in Figure 2AFigure 2


Relationship of coregulator and oestrogen receptor isoform expression to de novo tamoxifen resistance in human breast cancer.

Murphy LC, Leygue E, Niu Y, Snell L, Ho SM, Watson PH - Br. J. Cancer (2002)

Examples of immunohistochemistry using the IgYERβ503 antibody which recognises most ORβ isoforms: (A) normal human breast tissue; (B) ORβ negative human breast tumour, H-score=25; (C) ORβ low expressing human breast tumour, H-score=100; (D) ORβ high expressing human breast tumour, H-score=225.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2376286&req=5

fig2: Examples of immunohistochemistry using the IgYERβ503 antibody which recognises most ORβ isoforms: (A) normal human breast tissue; (B) ORβ negative human breast tumour, H-score=25; (C) ORβ low expressing human breast tumour, H-score=100; (D) ORβ high expressing human breast tumour, H-score=225.
Mentions: IgYERbeta503 is an antibody that recognises ligand binding and non-ligand binding ORβ protein isoforms (Horvath et al, 2001; Saji et al, 2000) and which we refer to as total ORβ protein. Normal breast tissue was used as a positive control and is shown in Figure 2AFigure 2

Bottom Line: All cases were oestrogen receptor +, node negative, primary breast tumours from patients who later had no disease progression (tamoxifen sensitive) or whose disease progressed while on tamoxifen (tamoxifen resistant).Using an antibody to oestrogen receptor-beta that detects multiple forms of this protein (total) but not an antibody that detects only full-length oestrogen receptor-beta 1, it was found that high total oestrogen receptor beta protein expressors were more frequently observed in tamoxifen sensitive tumours than resistant tumours (Fisher's exact test, P=0.046).Altogether, there is little evidence for altered coregulators expression in breast tumours that are de novo tamoxifen resistant.

View Article: PubMed Central - PubMed

Affiliation: Manitoba Institute of Cell Biology, University of Manitoba, Faculty of Medicine, Winnipeg, Manitoba, Canada, R3E OW3. lcmurph@cc.umanitoba.ca

Show MeSH
Related in: MedlinePlus